Terumo Corporation (TOKYO: 4543) approved, at the meeting of its Board of Directors held on May 10, 2012, the year-end dividends for the fiscal year ended March 31, 2012 as follows:
1. Details of Year-End Dividends
|Details of resolution||
Latest dividend forecast
(as of May 11, 2011)
Year-end dividends (Actual)
|Record date||March 31, 2012||March 31, 2012||March 31, 2011|
|Dividend per share||¥22.00||¥17.00||¥18.00|
|Total amount of dividends||¥4,177 million||-||¥3,417 million|
|Dividend payment starting date||June 29, 2012||-||June 30, 2011|
|Source of dividends||Retained earnings||-||Retained earnings|
2. Reasons for Determination of Dividend Amount
Our basic policy for profit allocation is to stably increase dividends to shareholders in accordance with business performance, investment plan and other aspects. In order to clarify the policy, the management will aim for the target dividend payout ratio of 30% over the medium to long term with the objective to increase returning profit to shareholders.
(Reference) Dividend Forecast and Actual
|Dividend per share|
|Record date||Interim dividend||Year-end dividend||Annual dividend (total)|
(ended March 31, 2012)
(ended March 31, 2011)
Note: The revised dividend for the year-end will be adopted on the condition of approval from shareholders in the general shareholders' meeting to be held on June 28, 2012.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.